ARCHIVES

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

DeVita Says He Did Not Agree To Include “Chop-Like” Elements In CCOP RFA But That He Would Consider It

March 19, 1982

NIH review finds 44 scientists violated ethics rules on industry consulting, House committee chairman says.

July 15, 2005

Analysis Reveals Patient Subset With Lower PFS in Phase III Trial

December 30, 2011

DCT To Examine Groups’ Studies, Directions, Role in 2000 A.D. Goal

June 8, 1984

Preventive Oncology Announcement Withdrawn For Modification

April 3, 1981

Clinical Trials: “Master Protocol” To Rely On Biomarkers In Testing Multiple Lung Cancer Agents

November 15, 2013